Advances of Targeted Therapy for Acute Myeloid Leukemia--Review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 1252-1256, 2023.
Article
Dans Chinois
| WPRIM
| ID: wpr-1009982
ABSTRACT
Acute myeloid leukemia (AML) has highly heterogeneous clinical manifestations and poor prognosis, and traditional chemotherapy is the main treatment. In recent years, with the in-depth development of next-generation sequencing technology, the treatment of AML is gradually exploring the precise targeted therapy in the direction of molecular biology and immunophenotype. The advent of various small-molecule inhibitors and immune-targeted drugs has brought hope to patients who cannot tolerate intensive chemotherapy or with relapsed/refractory AML. Compared with traditional chemotherapy, targeted therapy has the advantages of significant curative effect and fewer adverse effects. This article reviews the latest research progress of targeted drug therapy for AML.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Leucémie aigüe myéloïde
/
Protocoles de polychimiothérapie antinéoplasique
/
Immunothérapie adoptive
/
Immunothérapie
Limites du sujet:
Humains
langue:
Chinois
Texte intégral:
Journal of Experimental Hematology
Année:
2023
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS